Sun Pharmaceutical Industries Ltd.
Acme Plaza, Andheri - Kurla Road,
Andheri (East), Mumbai - 400 059, INDIA.
Tel. : (91-22) 2823 0102, 2821 2128, 6696 9696, 6696 9600
Fax : (91-22) 2821 2010
www.sunpharma.com
CIN : L24230GJ1993PLC019050

March 23, 2015

National Stock Exchange of India Ltd,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

BSE Ltd,
Market Operations Dept.
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sirs,

Sub: Intimation about the approval received from Reserve Bank of India and Competition Commission of India in respect of the Scheme of Arrangement between Ranbaxy Laboratories Limited and Sun Pharmaceutical Industries Ltd.

This is to inform you that the Company has today, received the approval from Reserve Bank of India (RBI) for (a) the issue of equity shares of Sun Pharmaceutical Industries Limited (Sun Pharma) to the Non Resident holders of securities of Ranbaxy Laboratories Limited (Ranbaxy) and (b) transfer of overseas investments held by Ranbaxy Laboratories Limited in its Joint Venture and Wholly Owned Subsidiaries to Sun Pharmaceutical Industries Limited, pursuant to the proposed merger of Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited through a Scheme of Arrangement.

Further the Company has also today, received the approval of the Competition Commission of India ("CCI") with respect to the divestment of all the seven products in compliance with the requirement of the CCI order dated December 5, 2014. Pursuant to this approval, Sun Pharma and Ranbaxy have also entered into a definitive agreement with Emcure Pharmaceuticals Ltd., for the aforementioned divestment. These products constitute less than 1% of the combined entity's revenues in India.

This is for your information and record.

Thanking you,

Yours faithfully,
For Sun Pharmaceutical Industries Ltd.,

Ashok I. Bhuta
Compliance Officer